A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 766 participants.
Also called NCT04161430
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 766 participants
- Registry
-
NCT04161430
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04161430. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-02 (actual); primary completion 2022-06-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- DBPR108; Placebo matching sitagliptin
- Intervention (Drug)
- Placebo matching DBPR108; Sitagliptin; DBPR108
- Intervention (Drug)
- Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Record details
- Record id
cardio:ct-nct04161430- Content hash
a0d2ef27cdc074dafc37e7a833ca6f71edc44842503c3e72eb0d177a6012722b